Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?

TheMotleyFool

0 0

Is Eli Lilly Stock a No-Brainer Buy After Its FDA Alzheimer's Disease Drug Win?: https://g.foolcdn.com/editorial/images/782797/scientists-smiling-and-shaking-hands.jpg

How does Eli Lilly (NYSE: LLY) follow up on gains of close to 60% in 2023 and so far in 2024? By winning a major U.S. Food and Drug Administration (FDA) approval.

Last week, the FDA approved Lilly's Kisunla (donanemab) in treating early symptomatic Alzheimer's disease. Is Eli Lilly stock a no-brainer buy after this key FDA approval?

There are now eight FDA-approved treatments for Alzheimer's disease. That might seem like a crowded market, but Kisunla should have a significant commercial opportunity.

Source Fool.com

Like: 0

LLY

Share